Menu
Recruiting NCT06691243

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

Phase II Interventional Cocaine Use Disorder HIV

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Semaglutide, Placebo.
Who it may be relevant to
Registry conditions: Cocaine Use Disorder, HIV. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation Of Semaglutide Safety and Tolerability in Adults With Cocaine Use Disorder With and Without HIV

Overview

The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's

Detailed description

STAC is a 16-week, double-blind, placebo-controlled, pilot, dose-escalation study that aims to determine the dose of semaglutide that is safe and tolerable in individuals with cocaine use disorder, including those with and without HIV; whether semaglutide improves drug use outcomes for cocaine use; and whether semaglutide improves cardiac and inflammatory biomarkers. Interested participants will be consented and screened, and after screening process is completed, all eligible participants who desire to continue with the study will be randomized either to semaglutide injections or placebo injections. Participants will receive semaglutide or placebo injections once a week from Day 0 through Week 16, and a final assessment will be completed at Week 16. Study visits will also intermittently complete labwork, medical examinations, clinical assessments and surveys.

Participants who consent to the optional MRI visits, will also complete MRI's at two timepoints: once before starting the study medication and once near Week 16.

Interventions

  • Drug Semaglutide
    The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.
  • Drug Placebo
    Patients randomized to placebo arm will receive placebo injection every week.

Primary outcome measures

  • Safety of semaglutide in patients with cocaine use disorder (CUD) with and without HIV [Time frame: 16 weeks]
  • Tolerability of semaglutide in patients with cocaine use disorder (CUD) with and without HIV [Time frame: 16 weeks]
Secondary outcome measures (12)
  • Determine if semaglutide improves cocaine use frequency in people with CUD with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide reduces cocaine use in people with CUD with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide reduces cocaine use in people with CUD with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide reduces cocaine craving for people with CUD with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide reduces drug use severity for people with CUD with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide reduces risk taking behavior in people with cocaine use disorder, with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide reduces impulsiveness in people with cocaine use disorder, with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide reduces compulsivity in people with cocaine use disorder, with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide impacts depression in people with cocaine use disorder, with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide impacts anxiety in people with cocaine use disorder, with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide impacts anhedonia in people with cocaine use disorder, with and without HIV [Time frame: 16 weeks]
  • Determine if semaglutide impacts sleep in people with cocaine use disorder, with and without HIV [Time frame: 16 weeks]

Eligibility criteria

Inclusion criteria

  • At least 18 years old
  • Meet criteria for CUD according to the Diagnostic and Statistical Manual Version 5
  • Used cocaine at least 7 out of the past 14 days
  • Body Mass Index between 20 - 50 kg/m2
  • English proficiency
  • In people of childbearing potential, agree to use an acceptable method of birth control

Exclusion criteria

  • Triglycerides > 500 mg/dL
  • History of gall bladder disease
  • Personal or family history of medullary thyroid carcinoma, or patients with a history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • History of diabetic retinopathy
  • Being prescribed glucose-lowering medications
  • An estimated glomerular filtration rate of less than 45 ml/min
  • Lifetime history of taking semaglutide or other GLP-1 RAs
  • Current suicidal ideation or suicide attempts within the past 24 months
  • Present diagnosis of diabetes mellitus OR screening hemoglobin A1C >/= 6.5
  • Use of weight-lowering medications
  • History of gastric bypass surgery
  • History of myocardial infarction or stroke within the past 12 months
  • Pregnant, breastfeeding, or the patient intends to become pregnant during the next four months
  • Any contraindicated medical issues identified by the study investigators
  • Risk of conditions that are under Warning and Precautions section of OZEMPIC and WEGOVY including but not limited to known history or current report of clinically relevant hypoglycemia, gastroparesis, or pancreatic disease.
  • Calcitonin value equal to or above 50 ng/L
  • If completing the MRI portion of the study: claustrophobia or physical issues preventing MRI scan
  • If completing the MRI portion of the study: presence of a metal device in the body (e.g. pacemaker. Infusion pump, aneurysm clip, metal prosthesis or plate

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

United States · 2 centers
  • Institute of Human Virology at the University of Maryland School of Medicine — Washington D.C.
  • Institute of Human Virology at the University of Maryland School of Medicine — Baltimore

Identifiers

NCT: NCT06691243 · HP-00112237 · 75N90024C00036

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗